Regencell Bioscience Holdings Limited Stock Analysis & AI Score

Regencell Bioscience Holdings Limited (RGC) has an ST Score of 32.3 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate RGC a Hold. Our ST Score grades it C- (32.3/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B-, Profitability C-, Financial Strength C+, Momentum D+, Growth F.

Regencell Bioscience Holdings Limited (RGC) earns a valuation grade of B-, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Regencell Bioscience Holdings Limited (RGC) earns a growth grade of F, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Regencell Bioscience Holdings Limited (RGC) earns a profitability grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Regencell Bioscience Holdings Limited (RGC) earns a financial strength grade of C+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

Regencell Bioscience Holdings Limited (RGC) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.